EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals (EYPT) has granted non-statutory stock options to four new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on April 15, 2025, allow the purchase of up to 65,000 shares of EyePoint common stock at an exercise price of $5.67 per share.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint through the applicable dates.
EyePoint Pharmaceuticals (EYPT) ha concesso opzioni azionarie non statutarie a quattro nuovi dipendenti come premi di incentivo al di fuori del suo Piano di Incentivi a Lungo Termine 2023. Le assegnazioni, approvate dal Comitato per la Remunerazione il 15 aprile 2025, consentono l'acquisto di un massimo di 65.000 azioni ordinarie di EyePoint a un prezzo di esercizio di 5,67 $ per azione.
Le opzioni hanno una durata di dieci anni e seguono un piano di maturazione quadriennale: il 25% matura al primo anniversario, mentre le azioni rimanenti maturano in rate mensili uguali nei tre anni successivi. La maturazione è subordinata alla permanenza in servizio presso EyePoint fino alle date previste.
EyePoint Pharmaceuticals (EYPT) ha otorgado opciones sobre acciones no estatutarias a cuatro nuevos empleados como premios de incentivo fuera de su Plan de Incentivos a Largo Plazo 2023. Las concesiones, aprobadas por el Comité de Compensación el 15 de abril de 2025, permiten la compra de hasta 65,000 acciones comunes de EyePoint a un precio de ejercicio de 5,67 $ por acción.
Las opciones tienen un plazo de diez años y siguen un calendario de adquisición de derechos de cuatro años: el 25 % se adquiere en el primer aniversario, y el resto se adquiere en cuotas mensuales iguales durante los siguientes tres años. La adquisición está condicionada a la continuidad laboral en EyePoint hasta las fechas correspondientes.
EyePoint Pharmaceuticals (EYPT)는 2023년 장기 인센티브 계획 외에 유인책으로 네 명의 신입 직원에게 비법정 주식매수선택권을 부여했습니다. 2025년 4월 15일 보상위원회에서 승인된 이 부여는 주당 5.67달러의 행사 가격으로 최대 65,000주의 EyePoint 보통주를 구매할 수 있게 합니다.
옵션은 10년 기간이며 4년 베스팅 일정에 따릅니다: 1주년에는 25%가 베스팅되고, 나머지 주식은 이후 3년 동안 매월 동일한 비율로 베스팅됩니다. 베스팅은 해당 날짜까지 EyePoint에서 계속 근무하는 조건입니다.
EyePoint Pharmaceuticals (EYPT) a accordé des options d'achat d'actions non statutaires à quatre nouveaux employés en tant que récompenses incitatives hors de son Plan d'Incitations à Long Terme 2023. Les attributions, approuvées par le Comité de Rémunération le 15 avril 2025, permettent l'achat de jusqu'à 65 000 actions ordinaires EyePoint à un prix d'exercice de 5,67 $ par action.
Les options ont une durée de dix ans et suivent un calendrier d'acquisition sur quatre ans : 25 % sont acquis à la première année, le reste étant acquis par versements mensuels égaux sur les trois années suivantes. L'acquisition est conditionnée à la poursuite de l'emploi chez EyePoint jusqu'aux dates concernées.
EyePoint Pharmaceuticals (EYPT) hat vier neuen Mitarbeitern außerhalb seines Langfristigen Anreizplans 2023 nicht-statutarische Aktienoptionen als Anreiz gewährt. Die am 15. April 2025 vom Vergütungsausschuss genehmigten Zuteilungen ermöglichen den Kauf von bis zu 65.000 EyePoint-Stammaktien zu einem Ausübungspreis von 5,67 $ pro Aktie.
Die Optionen haben eine Laufzeit von zehn Jahren und folgen einem vierjährigen Vesting-Plan: 25 % werden am ersten Jahrestag fällig, die restlichen Aktien werden über die folgenden drei Jahre in gleichen monatlichen Raten vestet. Das Vesting ist an eine fortlaufende Beschäftigung bei EyePoint bis zu den jeweiligen Terminen gebunden.
- Company demonstrates ability to attract new talent with equity compensation
- Potential future dilution from 65,000 new stock options
WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 65,000 shares of EyePoint common stock to four new employees. The stock options were granted on April 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
For EyePoint:
Investors:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
How many shares are included in EyePoint's (EYPT) April 2025 employee stock option grants?
What is the exercise price for EYPT's April 2025 employee stock options?
What is the vesting schedule for EyePoint's April 2025 employee stock options?
How long is the term of EYPT's April 2025 employee stock options?
